Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
-
Neurogastroenterol. Motil. · Dec 2011
Randomized Controlled Trial Multicenter StudyEfficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
The 5-HT(3) receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT(3) receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). ⋯ Ramosetron 5μg once daily is as effective as mebeverine three times daily in male patients with IBS-D.